Directorate Change

RNS Number : 4361I

RUA Life Sciences PLC

11 December 2020

 

 RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Directorate Change

RUA Life Sciences plc (AIM:RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, a long-term implantable biostable polymer, announces that Gordon Wright has resigned as a non-executive Director of the Company with effect from 10 December 2020.

As previously reported in the Company's audited results for the year ended 31 March 2020, Gordon, who was the founder of the predecessor AorTech business, has decided to retire from the Board now that the business has been re-established with an exciting future ahead of it. The Directors wish to thank Gordon for his support and guidance over the years and look forward to working with him in his new role as Honorary Life President.

The search for a replacement non-executive Director who will also chair the Company's audit committee is nearing completion and a further announcement will be made in due course.

For further information contact:

RUA Life Sciences plc    Tel: [phone]

Bill Brown, Executive Chairman       

Shore Capital          Tel: [phone]

Tom Griffiths / David Coaten     

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon^TM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon^TM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision. 

Elast-Eon ™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:  

RUA Medical :	End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials :	Licensor of Elast-EonTM polymers to the medical device industry.
RUA Vascular :	Development of large bore polymer sealed grafts and soft tissue patches.
RUA Structural Heart :	Development of tri leaflet polymeric heart valves.

 

END

 

 

BOAZFLFFBLLZFBX